Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells
Class I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen but also through Fc domain-mediated recruitment... Read More
Developing a Simple Antibody Dependent Cell-mediated Cytotoxicity Assay to Measure Target Cell Death
Most therapeutic antibodies have a Fab’ region that binds the antigen, and an Fc region which binds to and activates various cell... Read More